Related content

The metabolic effects of troglitazone in patients with diabetes and end-stage renal disease

By Mohideen Pharis   Bornemann Michael   Sugihara Jared   Genadio Viola   Sugihara Valerie   Arakaki Richard  

Endocrine Journal, Vol. 28, Iss. 2, 2005-11 ,pp. : 181-186

Humana Press, Inc

Access to resources Recommend Favorite

Calciphylaxis in end-stage renal disease patients

By Verdalles Ursula   García de Vinuesa Soledad   Luño José  

Nephrology Dialysis Transplantation, Vol. 27, Iss. 9, 2012-09 ,pp. : 3663-3663

Oxford University Press

Access to resources Recommend Favorite

Modified end-stage renal disease risk score for Chinese type 2 diabetic patients—the Hong Kong Diabetes Registry

By Yang X.   So W.   Kong A.   Ho C.   Lam C.   Ng M.   Lyu R.   Yin D.   Chow C.   Cockram C.   Tong P.   Chan J.  

Diabetologia, Vol. 50, Iss. 6, 2007-06 ,pp. : 1348-1350

Springer Publishing Company

Access to resources Recommend Favorite

CD2AP is associated with end-stage renal disease in patients with type 1 diabetes

By Hyvönen Mervi   Ihalmo Pekka   Sandholm Niina   Stavarachi Monica   Forsblom Carol   McKnight Amy   Lajer Maria   Maestroni Anna   Lewis Gareth   Tarnow Lise   Maestroni Silvia   Zerbini Gianpaolo   Parving Hans-Henrik   Maxwell Alexander   Groop Per-Henrik   Lehtonen Sanna  

Acta Diabetologica, Vol. 50, Iss. 6, 2013-12 ,pp. : 887-897

Springer Publishing Company

Access to resources Recommend Favorite

ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease

By Boger R.H.   Zoccali C.  

Atherosclerosis, Supplements, Vol. 4, Iss. 4, 2003-12 ,pp. : 23-28

Elsevier

Access to resources Recommend Favorite